Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CH
obligations may continue. See	

## HANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Sinha Vikas  (Last) (First) (Middle)  C/O ALEXION PHARMACUETICALS, INC.  352 KNOTTER DRIVE							2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ ALXN ]								ionship of Reporting Pers all applicable) Director Officer (give title below)		rson(s) to Issuer  10% Owner  Other (specify below)	
							3. Date of Earliest Transaction (Month/Day/Year) 03/20/2012							Below,	SVP & CFO			
(Street) CHESHIRE CT 06410 (City) (State) (Zip)					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	on-Deri	vativ	e Se	curit	ties Ac	quired,	Di	sposed o	f, or Be	neficial	ly Owned	l			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D.				r) Ex	A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			Benefic Owned	es ially Following	Form (D) o	n: Direct or Indirect onstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock, par value \$.0001 per share 03/20/2					/2012	012			M		21,996(1	) A	\$10.2	9 38	385,384		D	
Common Stock, par value \$.0001 per share 03/20/2					/2012	012			S		21,996(1	) D	\$89.93	36	3,388	D		
		-	Table II								posed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amount or Number of Shares					
Option to Purchase Common Stock	\$10.29	03/20/2012			M			21,996	04/15/20	07	01/15/2017	Common Stock, par value \$.0001 per share	21,996	\$0	0		D	

## **Explanation of Responses:**

- 1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$89.90 \$90.90. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

/s/ Vikas Sinha

03/22/2012

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.